Literature DB >> 27900037

Long term results of hepatic resection or orthotopic liver transplantation in patients with liver metastases from gastrointestinal neuroendocrine tumors.

Enrico Maria Pasqual1, Serena Bertozzi1, Ambrogio P Londero2, Stefano Bacchetti1, Dario Lorenzin1, Alberto Pasqualucci3, Federico Moccheggiani4, Alen Federici4, Marco Vivaverlli4, Andrea Risaliti1.   

Abstract

Hepatic metastases are one of the most important prognostic factors for survival among patients affected by gastrointestinal neuroendocrine tumors (NETs). The present study aims to evaluate the impact of surgery, including hepatic resection or orthotopic liver transplantation (OLT), on the outcome of patients affected by hepatic metastases from NETs, in terms of overall survival (OS). In this multicentric retrospective study, data was collected on 26 patients, who underwent surgery for hepatic metastases from NETs in two Italian University Clinics between January 1990 and December 2012; of which, 22 patients underwent hepatic resective surgery and 4 patients OLT. Hepatic metastases were synchronous in the 53.8% of cases and metachronous in the 46.2% of cases. The median number of resected hepatic metastases was 3. Surgical radicalness (R0) was reached in the 84.6% of cases. In total, 57.7% of patients had a recurrence, 66.7% of which were intra- and 33.3% extra-hepatic. The OS of patients that underwent hepatic resections and OLT was 44.9% [95% confidence interval (CI95), 26.0-77.7%] and 50% (CI95, 12.5-100.0%) at 5 years, respectively. Although the data regarding the survival of patients receiving surgery for hepatic metastases from NETs are encouraging, randomized clinical trials are necessary to more adequately evaluate the effect of surgery on survival of this group of patients.

Entities:  

Keywords:  gastroenteropancreatic neuroendocrine tumors; hepatic resection; liver metastases; orthotopic liver transplantation; overall survival

Year:  2016        PMID: 27900037      PMCID: PMC5103983          DOI: 10.3892/ol.2016.5045

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  Right lobe living related graft loss due to intrahepatic multiple arterio-portal fistulas.

Authors:  G L Adani; U Baccarani; A Risaliti; M Sainz-Barriga; D Lorenzin; F Bresadola
Journal:  Transplant Proc       Date:  2004-11       Impact factor: 1.066

2.  Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?

Authors:  Vincenzo Mazzaferro; Andrea Pulvirenti; Jorgelina Coppa
Journal:  J Hepatol       Date:  2007-07-26       Impact factor: 25.083

Review 3.  New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?

Authors:  Barbro Eriksson
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

Review 4.  Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review.

Authors:  Eliano Bonaccorsi-Riani; Carlos Apestegui; Anne Jouret-Mourin; Christine Sempoux; Pierre Goffette; Olga Ciccarelli; Ivan Borbath; Catherine Hubert; Jean François Gigot; Ziad Hassoun; Jan Lerut
Journal:  Transpl Int       Date:  2010-05-05       Impact factor: 3.782

Review 5.  Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract.

Authors:  Otto Rorstad
Journal:  J Surg Oncol       Date:  2005-03-01       Impact factor: 3.454

6.  Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery.

Authors:  D Jaeck; E Oussoultzoglou; P Bachellier; P Lemarque; J C Weber; H Nakano; P Wolf
Journal:  World J Surg       Date:  2001-06       Impact factor: 3.352

Review 7.  Current knowledge on diagnosis and staging of neuroendocrine tumors.

Authors:  Kjell Oberg; Daniel Castellano
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

Review 8.  Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours.

Authors:  R Srirajaskanthan; C Toumpanakis; T Meyer; M E Caplin
Journal:  Aliment Pharmacol Ther       Date:  2009-03-02       Impact factor: 8.171

9.  Aggressive surgery for metastatic liver neuroendocrine tumors.

Authors:  Jeffrey A Norton; Robert S Warren; Mary G Kelly; Marlene B Zuraek; Robert T Jensen
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

10.  Description of patients with midgut carcinoid tumours: clinical database from a Danish centre.

Authors:  Karen Marie Nykjaer; Henning Grønbaek; Dennis Tønner Nielsen; Peer Christiansen; Lone Bording Astrup
Journal:  In Vivo       Date:  2007 Jul-Aug       Impact factor: 2.155

View more
  1 in total

Review 1.  Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor.

Authors:  Alexander R Siebenhüner; Melanie Langheinrich; Juliane Friemel; Niklaus Schäfer; Dilmurodjon Eshmuminov; Kuno Lehmann
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.